Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 713,658
  • Shares Outstanding, K 118,943
  • Annual Sales, $ 207,740 K
  • Annual Income, $ -143,590 K
  • 60-Month Beta 1.78
  • Price/Sales 3.48
  • Price/Cash Flow N/A
  • Price/Book 1.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.43
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.53
  • Prior Year -0.91
  • Growth Rate Est. (year over year) +52.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.99 +102.68%
on 11/13/19
6.56 -7.62%
on 11/29/19
+2.17 (+55.78%)
since 11/05/19
3-Month
2.99 +102.68%
on 11/13/19
6.56 -7.62%
on 11/29/19
+1.97 (+48.17%)
since 09/05/19
52-Week
2.99 +102.68%
on 11/13/19
10.45 -42.01%
on 12/13/18
-2.26 (-27.16%)
since 12/04/18

Most Recent Stories

More News
Arrowhead Pharma has the Best Relative Performance in the Biotechnology Industry (ARWR, AKBA , SGMO , BLUE , CCXI )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AKBA : 6.06 (+1.00%)
SGMO : 11.60 (-0.90%)
ARWR : 65.53 (-1.40%)
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, granted 14 newly-hired employees...

AKBA : 6.06 (+1.00%)
Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) Stock

Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately.

AKBA : 6.06 (+1.00%)
Akebia Therapeut has the Best Relative Performance in the Biotechnology Industry (AKBA , BPMC , ADMS , ARWR, FGEN )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ADMS : 6.52 (+1.87%)
AKBA : 6.06 (+1.00%)
BPMC : 74.56 (-0.72%)
ARWR : 65.53 (-1.40%)
Look for Shares of Akebia Therapeut to Potentially Pullback after Yesterday's 11.52% Rise

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $5.53 to a high of $6.56. Yesterday, the shares gained 11.5%, which took the trading range above the 3-day high of...

AKBA : 6.06 (+1.00%)
Akebia Therapeutics to Present at Upcoming Investor Conferences

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, today announced its executives...

AKBA : 6.06 (+1.00%)
Watch for Akebia Therapeut to Potentially Pullback After Gaining 8.49% Yesterday

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $3.17 to a high of $3.65. Yesterday, the shares gained 8.5%, which took the trading range above the 3-day high of...

AKBA : 6.06 (+1.00%)
Look for Shares of Akebia Therapeut to Potentially Rebound after Yesterday's 7.96% Sell Off

Akebia Therapeut (NASDAQ:AKBA) traded in a range yesterday that spanned from a low of $2.99 to a high of $3.30. Yesterday, the shares fell 8.0%, which took the trading range below the 3-day low of $3.23...

AKBA : 6.06 (+1.00%)
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 24.32% and -2.09%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?...

AKBA : 6.06 (+1.00%)
Akebia Therapeutics: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Akebia Therapeutics Inc. (AKBA) on Tuesday reported a loss of $54.6 million in its third quarter.

AKBA : 6.06 (+1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AKBA with:

Business Summary

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 6.37
1st Resistance Point 6.21
Last Price 6.06
1st Support Level 5.91
2nd Support Level 5.77

See More

52-Week High 10.45
Fibonacci 61.8% 7.60
Fibonacci 50% 6.72
Last Price 6.06
Fibonacci 38.2% 5.84
52-Week Low 2.99

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar